Peptides
Human Growth Hormone (HGH)
Also called HGH · Somatropin · GH
Physique users seek HGH for a leaner look, muscle fullness and better recovery; some also hope for better sleep. These are different goals from treating diagnosed growth-hormone deficiency. Extra lean mass can include water, and swelling, numb hands or worse glucose control can outweigh the hoped-for changes.
Dosage & duration
Separate medical starting dose and nonmedical author examples; not interchangeable treatment plans
Non-weight-based starting example
Product label- Dose
- About 0.2 mg/day (range 0.15–0.30 mg/day)
- How often
- Once-daily subcutaneous injection
- How long
- Ongoing replacement with reassessment
Starting amounts, not maintenance targets or bodybuilding advice; dose is adjusted clinically.
Sources: 3
Reported bodybuilding use
Reported use · unapproved regimen- Dose
- 2 or 4 IU total per day
- How often
- Daily injected total; author discusses divided doses
- How long
- No fixed course specified
Author opinion in an anabolic-steroid-cycle context, not a tested safe regimen. The profile describes IM/SC use; no route conversion or stack advice is provided here.
HGH in perspective
HGH goals and everyday trade-offs
What people seek
-
Physique and recovery
A leaner look, fuller muscles and better workout recovery are reported goals.
What can interfere
-
Fluid and glucose changes
Swelling, numb hands and worse glucose control can outweigh the hoped-for changes.
Medical replacement Treating diagnosed deficiency has a different goal and is adjusted to response and IGF-1.
Why do physique users research HGH?
HGH discussions center on staying leaner, looking fuller and feeling better recovered. Some people also report better sleep or question whether the expense feels worthwhile. Other users describe numb hands, fluid retention or little noticeable benefit. Many reports involve other drugs, so they cannot isolate HGH’s contribution.
Does more lean mass mean more muscle?
Not necessarily. In an eight-week randomized study of 96 recreational athletes, HGH reduced fat mass, while the lean-mass increase reflected extra fluid outside cells. Sprint capacity improved, but strength, jump power and endurance did not significantly improve. That short study does not settle longer-term bodybuilding results or safety; it does show why a fuller appearance is not the same as extra contractile muscle.
Medical amounts versus physique reports
The opening dose guide separates adult-deficiency treatment from attributed nonmedical examples. Product units and syringe volume are different: a syringe marking is not automatically an IU of growth hormone. Neither a reported schedule nor a blood-level curve establishes a best cycle or best injection time for muscle growth.
What can get in the way?
The Genotropin label warns about fluid retention, joint discomfort, carpal-tunnel-type symptoms and impaired glucose control. Painful or numb hands can make training harder rather than demonstrating that the product is working well. These effects deserve medical review, not an assumption that another drug is needed to counter them.
What is the curve showing?
The model illustrates administered somatropin timing. It is not a graph of IGF-1, muscle growth, fat loss or natural GH pulses, and the short blood curve does not define treatment duration.
Dose references and context Existing reported protocols; not personal dosing instructions
This older catalog material includes research and community reports. It has not all been source-checked in this page update and should not be treated as a dosing recommendation.
Adult GH deficiency: GENOTROPIN label example
Approximately 0.2 mg/day initially (label range 0.15–0.30 mg/day) · Subcutaneous · Once daily
Product-specific adult replacement context. Titration depends on response, IGF-1 and tolerability; not a performance regimen.
Model details: Human Growth Hormone (HGH) · estimated
How to read this estimate
Estimated from study endpoints; the curve between measurements is reconstructed. Compare amounts and timing in mg.
A concentration estimate reconstructed from the stated source dose and timing.
Assumptions, calculation and sources
Omnitrope 5mg/1.5mL solution; study EP2K-00-PhIAQ. subcutaneous. 24 healthy adults (12 men and 12 women) with endogenous GH suppressed during the study; fixed endpoints, no assumed body weight.
somatropin/GH concentration from the source study: estimated concentration in serum (ng/mL).
Omnitrope solution single-dose study EP2K-00-PhIAQ, N=24; apparent SC tail, not intrinsic IV elimination.
- Calibration dose
- 5 mg
- Reported calibration peak
- 52 ng/mL
- Peak timing used
- 3 hours
- Terminal half-life used
- 2.4 hours
- Reconstructed absorption rate
- 0.3822114 /hour
- Observed Cmax already includes absorption; do not apply F again
- Study EP2K-00-PhIAQ used a 25-hour octreotide infusion to suppress endogenous GH secretion. Its serum somatropin measurements do not describe natural GH pulses.
- Dose scaling and repeated-dose superposition use fixed parameters; the example dose does not calibrate the curve.
- Reconstruction of one named healthy-volunteer study; not a universal HGH brand, IGF-1 response or endogenous secretion model.
- SC terminal slope may reflect absorption. Inferred first-order rates reproduce endpoint shape, not measured mechanistic absorption/elimination constants.
- Do not infer a study weight from 5mg or use UI default as calibration dose.
- Other monograph cohorts differ; no claim of bioequivalence of every nonapproved preparation.
- The selected exogenous somatropin study does not model endogenous GH pulses or every HGH formulation.
- Health Canada OMNITROPE product monograph, Table 20, printed pp59–60, EP2K-00-PhIAQ
Healthy adult volunteers, single 5 mg SC Omnitrope 5 mg/1.5mL solution. Mean Cmax 52±10 µg/L, median Tmax 3 h (2–8), terminal t1/2 2.4±0.7 h, AUCinf426±45 h·µg/L. One µg/L equals one ng/mL.
- FDA Omnitrope medical review — EP2K-00-PhIAQ, printed page 19
The study used 24 healthy volunteers (12 men and 12 women), 5 mg SC doses and a 25-hour octreotide infusion to suppress endogenous GH. PK assessments used somatropin serum concentrations.
- Health Canada Omnitrope monograph — EP2K-00-PhIAQ design and Tables 20–21
Study design confirms 24 healthy adults, 12 men and 12 women, and endogenous GH suppression. Table 21 reproduces the selected 52 µg/L peak, 3-hour peak time and 2.4-hour half-life.
- Wilton et al. 1988, PK profile of IV and SC recombinant HGH
Original CSV provenance: 0.1 IU/kg SC, Cmax53±4.2 mU/L, Tmax5.3±0.6h, absorption-limited tail248±55min; this does not directly support the current literal peak.
- GENOTROPIN label 12.3
Formulation/cohort differences matter: adult GHD0.03mg/kg at1.3mg/mL has peak12.4ng/mL around6h; formulation comparisons show different exposure.
Estimate hgh-source-estimate-2026-10 · version 1
Common questions
Is adult GH treatment a fixed cycle?
For diagnosed deficiency it is replacement with follow-up, not a standard bodybuilding cycle.
Is an IU the same as a syringe unit?
No. IU describes drug activity; syringe marks describe volume. Product concentration determines the relationship.
Sources Labels, studies and notes behind this guide
Catalog evidence: Human clinical trials. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-10, 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Why lifters discuss it
- These are reported goals; a positive experience does not establish which changes HGH caused.
- Medical use
- Clinicians adjust adult treatment using response, IGF-1 and tolerability.
- Main trade-off
- Swelling and joint or hand symptoms are not proof of muscle growth.
- 1. GENOTROPIN prescribing information
Current label: adult GHD indication, response/IGF-1 titration, fluid retention and glucose warnings; SC half-life 3 hours in GHD adults.
- 2. Meinhardt et al. — randomized study in recreational athletes (2010)
Primary-study abstract: 96 recreational athletes, eight weeks. Separates fluid-related lean-mass change and sprint capacity from strength, power and endurance.
- 3. Pfizer — Genotropin prescribing information
Adult deficiency starting example 0.2 mg/day (0.15–0.30), adjusted to response/IGF-1; fluid retention and impaired glucose tolerance precautions.
- 4. Health Canada OMNITROPE product monograph, Table 20, printed pp59–60, EP2K-00-PhIAQ
Healthy adult volunteers, single 5 mg SC Omnitrope 5 mg/1.5mL solution. Mean Cmax 52±10 µg/L, median Tmax 3 h (2–8), terminal t1/2 2.4±0.7 h, AUCinf426±45 h·µg/L. One µg/L equals one ng/mL.
- 5. FDA Omnitrope medical review — EP2K-00-PhIAQ, printed page 19
The study used 24 healthy volunteers (12 men and 12 women), 5 mg SC doses and a 25-hour octreotide infusion to suppress endogenous GH. PK assessments used somatropin serum concentrations.
- 6. Health Canada Omnitrope monograph — EP2K-00-PhIAQ design and Tables 20–21
Study design confirms 24 healthy adults, 12 men and 12 women, and endogenous GH suppression. Table 21 reproduces the selected 52 µg/L peak, 3-hour peak time and 2.4-hour half-life.
- 7. Wilton et al. 1988, PK profile of IV and SC recombinant HGH
Original CSV provenance: 0.1 IU/kg SC, Cmax53±4.2 mU/L, Tmax5.3±0.6h, absorption-limited tail248±55min; this does not directly support the current literal peak.
- 8. GENOTROPIN label 12.3
Formulation/cohort differences matter: adult GHD0.03mg/kg at1.3mg/mL has peak12.4ng/mL around6h; formulation comparisons show different exposure.
Related compounds and examples
Related compounds
MK-677 (Ibutamoren)
MK-677 explained: appetite, sleep and muscle expectations, research doses and water-weight trade-offs.
MGF (Mechano Growth Factor)
MGF for muscle recovery and growth: reported dose claims, workout timing and the difference from PEG-MGF.
PEG-MGF (Pegylated MGF)
PEG-MGF versus MGF: muscle-growth claims, reported schedules and the limits of the longer-lasting promise.